journal
MENU ▼
Read by QxMD icon Read
search

Seminars in Nephrology

journal
https://www.readbyqxmd.com/read/30177025/treatment-of-iga-nephropathy-evolution-over-half-a-century
#1
REVIEW
Jonathan Barratt, Sydney C W Tang
Fifty years into the original description of IgA nephropathy, there is still no specific therapy for this condition and general measures including blood pressure control with blockers of the renin-angiotensin-aldosterone system and salt restriction remain the cornerstone to slow disease progression. Although the paucity in treatment advances could be related to the disease's complex pathogenesis, which requires multiple hits, heterogeneity as reflected by diverse ethnic differences, and genetic predisposition and histopathologic variations, many nonspecific and immunomodulatory agents have been tested with variable degrees of success and tribulations...
September 2018: Seminars in Nephrology
https://www.readbyqxmd.com/read/30177024/biomarkers-and-precision-medicine-in-iga-nephropathy
#2
REVIEW
Francesco Paolo Schena, Sharon Natasha Cox
The field of biomarker research in IgA nephropathy has experienced a major boost in recent years with the publication of a large number of scientific reports. Candidate biomarkers from blood, urine, and renal tissue obtained through the use of clinical chemistry, molecular biology, and omics have been proposed for translation in clinical practice. Nevertheless, individual biomarkers often lack sensitivity and specificity with the consequent impairment of disease specificity. This review, moving on from the analysis of the four-hit hypothesis, illustrates the biomarkers linked to the abnormal glycosylation process of IgA1 and the immune complex formation...
September 2018: Seminars in Nephrology
https://www.readbyqxmd.com/read/30177023/murine-models-of-human-iga-nephropathy
#3
REVIEW
Hitoshi Suzuki, Yusuke Suzuki
IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis in the world. IgAN is characterized by mesangial deposits of IgA1-containing immune complexes. IgA1 usually co-deposits with complement C3 and variable IgG and/or IgM. Exactly 50 years have passed since IgAN was described, however, the pathogenesis of disease onset and progression have not been fully clarified. Animal models can re-create the complex immunologic microenvironments that foster human autoimmunity and nephritis and provide access to tissue compartments not readily examined in patients...
September 2018: Seminars in Nephrology
https://www.readbyqxmd.com/read/30177022/the-gut-renal-connection-in-iga-nephropathy
#4
REVIEW
Rosanna Coppo
The connection between a dysregulated gut-associated lymphoid tissue and IgA nephropathy (IgAN) was supposed decades ago after the observation of increased association of IgAN with celiac disease. Pivotal studies have shown a role for alimentary antigens, particularly gliadin in developing IgAN in BALB/c mice, and a reduction in IgA antigliadin antibodies and proteinuria was reported after gluten free-diet in patients with IgAN. Recently a genome-wide association study showed that most loci associated with IgAN also are associated with immune-mediated inflammatory bowel diseases, maintenance of the intestinal barrier, and response to gut pathogens...
September 2018: Seminars in Nephrology
https://www.readbyqxmd.com/read/30177021/role-of-the-spleen-tyrosine-kinase-pathway-in-driving-inflammation-in-iga-nephropathy
#5
REVIEW
Stephen McAdoo, Frederick W K Tam
IgA nephropathy is the most common type of primary glomerulonephritis worldwide. At least 25% of patients may progress to kidney failure requiring dialysis or transplantation. Treatment of IgA nephropathy using generalized immunosuppression is controversial, with concerns regarding the balance of safety and efficacy in a nonspecific approach. This review describes the recent scientific evidence, and a current clinical trial, investigating whether spleen tyrosine kinase (SYK) may be a novel and selective therapeutic target for IgA nephropathy...
September 2018: Seminars in Nephrology
https://www.readbyqxmd.com/read/30177020/role-of-mesangial-podocytic-tubular-cross-talk-in-iga-nephropathy
#6
REVIEW
Joseph C K Leung, Kar Neng Lai, Sydney C W Tang
IgA nephropathy (IgAN), a common primary glomerulonephritis worldwide, is associated with a substantial risk of progression to end-stage renal failure. The disease runs a highly variable clinical course with frequent involvement of tubulointerstitial damage. A subgroup of IgAN with proximal tubular epithelial cells (PTECs) and tubulointerstitial damage often is associated with rapid progression to end-stage renal failure. Human mesangial cell-derived mediators lead to podocyte and tubulointerstitial injury via mesangial-podocytic-tubular cross-talk...
September 2018: Seminars in Nephrology
https://www.readbyqxmd.com/read/30177019/histologic-classification-of-iga-nephropathy-past-present-and-future
#7
REVIEW
Maria F S Soares, Ian S D Roberts
IgA nephropathy (IgAN) is the most common glomerulonephritis worldwide. Since its description in 1968, a number of histologic descriptions and classification systems have emerged, the most recent of which is the Oxford Classification of IgAN. We present a historical panorama of histologic classifications of IgAN and discuss the most recent developments, updates, and future challenges of the Oxford Classification of IgAN.
September 2018: Seminars in Nephrology
https://www.readbyqxmd.com/read/30177018/aberrant-glycosylation-of-the-iga1-molecule-in-iga-nephropathy
#8
REVIEW
Jan Novak, Jonathan Barratt, Bruce A Julian, Matthew B Renfrow
IgA nephropathy, the most common primary glomerulonephritis in the world and a frequent cause of end-stage renal disease, is characterized by typical mesangial deposits of IgA1, as described by Berger and Hinglaise in 1968. Since then, it has been discovered that aberrant IgA1 O-glycosylation is involved in disease pathogenesis. Progress in glycomic, genomic, clinical, analytical, and biochemical studies has shown autoimmune features of IgA nephropathy. The autoimmune character of the disease is explained by a multihit pathogenesis model, wherein overproduction of aberrantly glycosylated IgA1, galactose-deficient in some O-glycans, by IgA1-secreting cells leads to increased levels of circulatory galactose-deficient IgA1...
September 2018: Seminars in Nephrology
https://www.readbyqxmd.com/read/30177017/genetic-determinants-of-iga-nephropathy-eastern-perspective
#9
REVIEW
Ming Li, Xue-Qing Yu
IgA nephropathy (IgAN) is one of the most common primary glomerulonephritides throughout the world and a major cause of end-stage renal disease among the East Asian population. It is widely considered that genetic factors play an important role in the pathogenesis of IgAN. This article summarizes the recent achievements in the genetic studies of IgAN, focusing mainly on studies performed in East Asia, from the early association studies of candidate genes and family based designs, to the recent genome-wide association studies...
September 2018: Seminars in Nephrology
https://www.readbyqxmd.com/read/30177016/genetic-determinants-of-iga-nephropathy-western-perspective
#10
REVIEW
Y Dana Neugut, Krzysztof Kiryluk
IgA nephropathy (IgAN) represents a genetically complex multifactorial trait. Its prevalence and clinical features vary geographically, and the disease has a range of clinical presentations that suggest multiple subtypes. Although familial aggregation of IgAN has been reported and prior linkage studies have highlighted significant locus heterogeneity, specific genetic variants underlying familial IgAN have not yet been defined. Population-based genome-wide association studies (GWAS) have discovered nearly 20 IgAN risk loci, providing novel insights into disease epidemiology and molecular mechanisms, shifting old paradigms of the disease pathogenesis...
September 2018: Seminars in Nephrology
https://www.readbyqxmd.com/read/30177015/epidemiology-of-iga-nephropathy-a-global-perspective
#11
REVIEW
Francesco Paolo Schena, Ionut Nistor
IgA nephropathy (IgAN), or Berger's disease, is the most common primary glomerular disease worldwide, but varies largely in its geographic distribution. A systematic review of 1,619 publications from the five continental regions of the world was performed to assess the prevalence of IgAN in different worldwide regions and analyze factors responsible for geographic differences. All observational studies that described the prevalence and incidence data on glomerulonephritis were considered. IgAN is more frequent in Asian populations (45 cases per million population/y in Japan) than in Caucasians (31 cases per million population/y in France)...
September 2018: Seminars in Nephrology
https://www.readbyqxmd.com/read/30177014/an-overview-of-iga-nephropathy-50-years-on
#12
EDITORIAL
Sydney C W Tang
No abstract text is available yet for this article.
September 2018: Seminars in Nephrology
https://www.readbyqxmd.com/read/30082062/dialysis-patient-centeredness-and-precision-medicine-focus-on-incremental-home-hemodialysis-and-preserving-residual-kidney-function
#13
REVIEW
Nieltje Gedney, Kamyar Kalantar-Zadeh
An exponential interest in incremental transition to dialysis recently has emerged in lieu of outright three times/wk hemodialysis initiation as the standard of care. Incremental dialysis is consistent with precision medicine, given individualized dialysis dose adjustment based on patient's dynamic needs, leading to reduced patient suffering from longer or more frequent dialysis treatments and improved health-related quality of life. It includes twice-weekly or less frequent hemodialysis treatments with or without a low-protein diet on nondialysis days, or a shorter (<3 h) hemodialysis treatment three times per week or more frequent treatments, a useful approach for home hemodialysis initiation...
July 2018: Seminars in Nephrology
https://www.readbyqxmd.com/read/30082061/using-technology-to-inform-and-deliver-precise-personalized-care-to-patients-with-end-stage-kidney-disease
#14
REVIEW
Len Usvyat, Lorien S Dalrymple, Franklin W Maddux
Consistent with the increase of precision medicine, the care of patients with end-stage kidney disease (ESKD) requiring maintenance dialysis therapy should evolve to become more personalized. Precise and personalized care is nuanced and informed by a number of factors including an individual's needs and preferences, disease progression, and response to and tolerance of treatments. Technology can support the delivery of more precise and personalized care through multiple mechanisms, including more accurate and real-time assessments of key care elements, enhanced treatment monitoring, and remote monitoring of home dialysis therapies...
July 2018: Seminars in Nephrology
https://www.readbyqxmd.com/read/30082060/personalized-anemia-management-and-precision-medicine-in-esa-and-iron-pharmacology-in-end-stage-kidney-disease
#15
REVIEW
Michael E Brier, Adam E Gaweda, George R Aronoff
Substantial progress has been made in the application of computer-driven methods to provide erythropoietic dosing information for patients with anemia resulting from chronic kidney disease. Initial solutions were simply computerized versions of traditional paper-based anemia management protocols. True personalization was achieved through the use of advanced modeling techniques such as artificial neural networks, physiologic models, and feedback control systems. The superiority of any one technique over another has not been determined, but all methods have shown an advantage in at least one area over the traditional paper expert system used by most dialysis facilities...
July 2018: Seminars in Nephrology
https://www.readbyqxmd.com/read/30082059/personalized-management-of-bone-and-mineral-disorders-and-precision-medicine-in-end-stage-kidney-disease
#16
REVIEW
Anna Jovanovich, Jessica Kendrick
Chronic kidney disease mineral bone disorder (CKD-MBD) is common in end-stage renal disease and is associated with an increased risk of cardiovascular morbidity and mortality. Mainstays of treatment include decreasing serum phosphorus level toward the normal range with dietary interventions and phosphate binders and treating increased parathyroid hormone levels with activated vitamin D and/or calcimimetics. There is significant variation in serum levels of mineral metabolism markers, intestinal absorption of phosphorus, and therapeutic response among individual patients and subgroups of patients with end-stage renal disease...
July 2018: Seminars in Nephrology
https://www.readbyqxmd.com/read/30082058/precision-medicine-for-nutritional-management-in-end-stage-kidney-disease-and-transition-to-dialysis
#17
REVIEW
Angela Yee-Moon Wang, Kamyar Kalantar-Zadeh, Denis Fouque, Pieter T Wee, Csaba P Kovesdy, S Russ Price, Joel D Kopple
Chronic kidney disease (CKD) is a global public health burden. Dialysis is not only costly but may not be readily available in developing countries. Even in highly developed nations, many patients may prefer to defer or avoid dialysis. Thus, alternative options to dialysis therapy or to complement dialysis are needed urgently and are important objectives in CKD management that could have huge clinical and economic implications globally. The role of nutritional therapy as a strategy to slow CKD progression and uremia was discussed as early as the late 19th and early 20th century, but was only seriously explored in the 1970s...
July 2018: Seminars in Nephrology
https://www.readbyqxmd.com/read/30082057/precision-medicine-and-personalized-management-of-lipoprotein-and-lipid-disorders-in-chronic-and-end-stage-kidney-disease
#18
REVIEW
Elani Streja, Dan A Streja, Melissa Soohoo, Carola-Ellen Kleine, Jui-Ting Hsiung, Christina Park, Hamid Moradi
Precision medicine is an emerging field that calls for individualization of treatment strategies based on characteristics unique to each patient. In lipid management, current guidelines are driven mainly by clinical trial results that presently indicate that patients with non-dialysis-dependent chronic kidney disease (CKD) should be treated with a β-hydroxy β-methylglutaryl-CoA reductase inhibitor, also known as statin therapy. For patients with end-stage kidney disease (ESKD) being treated with hemodialysis, statin therapy has not been shown to successfully reduce poor outcomes in trials and therefore is not recommended...
July 2018: Seminars in Nephrology
https://www.readbyqxmd.com/read/30082056/patient-centered-approach-for-hypertension-management-in-end-stage-kidney-disease-art-or-science
#19
REVIEW
Elvira O Gosmanova, Csaba P Kovesdy
Hypertension is present in most patients with end-stage kidney disease initiating dialysis and management of hypertension is a routine but challenging task in everyday dialysis care. End-stage kidney disease patients are uniquely heterogeneous individuals with significant variations in demographic characteristics, functional capacity, and presence of concomitant comorbid conditions and their severity. Therefore, these patients require personalized approaches in addressing not only hypertension but related illnesses, while also accounting for overall prognosis and projected longevity...
July 2018: Seminars in Nephrology
https://www.readbyqxmd.com/read/30082055/precision-medicine-and-personalized-approach-to-renal-transplantation
#20
REVIEW
Donald C Dafoe, Ekamol Tantisattamo, Uttam Reddy
Successful renal transplantation is a highly effective endeavor that improves and prolongs the lives of patients with chronic kidney disease. Transplant surgery and immunosuppression carries risk and the demand for donor kidneys outstrips supply by far. These realities mandate thoughtful allocation and utilization of this limited resource to select candidates. As the criteria for candidates and donor grafts continue to expand, the field must adapt and seek new approaches. The complex process-from evaluation of candidates, transplant surgery, immunosuppression, and follow-up care after transplantation-is, of necessity, tightly structured and regulated...
July 2018: Seminars in Nephrology
journal
journal
28249
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"